Alnylam Pharmaceuticals Stock (NASDAQ: ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Quote.Headers.trade-ideas

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Biotech

Earnings

Earnings Beats

Large Cap

News

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

ALNY

FULC

ILMN

KRYS

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.

ALNY Down Despite Positive Data From Heart Disease Drug Study

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Health Care

Movers

BBIO

Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented at ESC Congress 2024. Regulatory submissions remain on track.

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

DoorDash

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H. Robinson Worldwide, and DoorDash.

DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

ALNYLAM PHARMACEUTICALS ORD

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 10 years by 3.01% on an annualized basis producing an average annual return of 13.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $32.89 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 10 years ago, it would be worth $3,656.71 today based on a price of $256.21 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726075837_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and maintains $220 price target.

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $295 to $307.

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.
The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in the overall population as well as the monotherapy population.
However, as a component of the primary endpoint, treatment with vutrisiran led to a 30% reduction in mortality in the monotherapy population in the double-blind period. Per management, this reduction was non-significant.
This might have hurt investors&#39; sentiments and resulted in the stock going down.
<h2>ALNY Stock Outperforming Industry</h2>
Shares of Alnylam have gained 37.3% so far this year compared with the industry&#39;s growth of 0.6%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/76266.jpg?v=875498674" />
Image Source: Zacks Investment Research
Please note that vutrisiran is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. This is also approved in the European Union for the same indication in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is marketed under the trade name Amvuttra in the United States and Europe.
In June 2024, Alnylam reported encouraging data from the phase III HELIOS-B study evaluating vutrisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. Shares of the company soared on this news.
The phase III HELIOS-B study enrolled 655 adult patients with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy who were divided equally to receive vutrisiran 25mg or placebo subcutaneously once every three months for up to 36 months.
Alnylam is gearing up to proceed with global regulatory submissions, including filing a supplemental new drug application for vutrisiran with the FDA using a Priority Review Voucher later in 2024.
<h2>Amvuttra, a Key Revenue Driver for ALNY</h2>
Amvuttra is currently the top contributor to Alnylam&#39;s top line. This drug generated sales worth $425.4 million in the first half of 2024, increasing 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from ALNY&#39;s Onpattro(patisiran).
Onpattro is also approved in the United States and European Union to treat ATTR amyloidosis in adults.
If approved forthe new indication, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR amyloidosis with cardiomyopathy. This is likely to boost sales further and will expand the eligible patient population for the drug in future quarters.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330592/alny-down-despite-positive-data-from-heart-disease-drug-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2330592">To read this article on Zacks.com click here.</a>

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 34.2% to $6.31 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares rose 17.62% to $10.48. The market value of their outstanding shares is at $549.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 14.96% to $0.19. The market value of their outstanding shares is at $2.2 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) stock increased by 14.95% to $4.06. The market value of their outstanding shares is at $5.3 million. </li>
<li>Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) shares moved upwards by 11.9% to $1.08. The market value of their outstanding shares is at $83.4 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares moved upwards by 11.41% to $8.49. The company's market cap stands at $307.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares declined by 48.3% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 27.95% to $0.98. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 15.18% to $0.95. The company's market cap stands at $17.5 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares decreased by 7.69% to $20.18. The market value of their outstanding shares is at $102.2 million. </li>
<li>Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares fell 7.5% to $265.51. The market value of their outstanding shares is at $34.0 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares declined by 6.42% to $1.75. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMEA

EKSO

LGMK

MLSS

NCNA

NUTX

SNPX

TOVX

VTAK

XCUR

12 Health Care Stocks Moving In Monday's Pre-Market Session

Investors with a lot of money to spend have taken a bullish stance on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALNY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Alnylam Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,479,365, and 7 are calls, for a total amount of $532,783.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $310.0 for Alnylam Pharmaceuticals over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Alnylam Pharmaceuticals options trades today is 608.25 with a total volume of 5,819.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Alnylam Pharmaceuticals's big money trades within a strike price range of $90.0 to $310.0 over the last 30 days.
<h3>Alnylam Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725049066_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.4</td>
<td>$18.2</td>
<td>$18.3</td>
<td>$260.00</td>
<td>$915.0K</td>
<td>70</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$177.5</td>
<td>$173.9</td>
<td>$173.9</td>
<td>$90.00</td>
<td>$173.9K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$14.8</td>
<td>$14.7</td>
<td>$14.7</td>
<td>$270.00</td>
<td>$151.4K</td>
<td>2.7K</td>
<td style="text-align: right;">323</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$22.6</td>
<td>$19.5</td>
<td>$22.0</td>
<td>$280.00</td>
<td>$110.0K</td>
<td>412</td>
<td style="text-align: right;">88</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$19.5</td>
<td>$20.99</td>
<td>$250.00</td>
<td>$103.9K</td>
<td>0</td>
<td style="text-align: right;">57</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Present Market Standing of Alnylam Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 3,753,765, the ALNY's price is down by -8.47%, now at $262.69. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What The Experts Say On Alnylam Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $264.2.
<ul>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Alnylam Pharmaceuticals, targeting a price of $233. </li>
<li>An analyst from Needham persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $320. </li>
<li>An analyst from Goldman Sachs has decided to maintain their Neutral rating on Alnylam Pharmaceuticals, which currently sits at a price target of $198. </li>
<li>An analyst from Raymond James has decided to maintain their Outperform rating on Alnylam Pharmaceuticals, which currently sits at a price target of $275. </li>
<li>An analyst from Barclays persists with their Overweight rating on Alnylam Pharmaceuticals, maintaining a target price of $295. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alnylam Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on ALNY Options

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s" rel="noreferrer noopener">revealed in June</a>.
The data were presented at the European Society of Cardiology Congress 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37491686/rochealnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-a" rel="noreferrer noopener">Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges</a>.
In the overall population, vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 28%, with similar reductions in the mortality and cardiovascular <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40647186/alnylam-presents-detailed-results-from-the-positive-helios-b-phase-3-study-of-vutrisiran-in-patien" rel="noreferrer noopener">events components of the endpoint</a>.
Mortality in this population was significantly reduced by 31% and by 36% up to 42 months.
In the monotherapy population, vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 33% and reduced the risk of mortality by 35% up to 42 months.
A non-significant reduction of 30% in mortality was observed (nominal p-value 0.1179) in the monotherapy population.
Vutrisiran treatment was also associated with benefits versus placebo across multiple well-established clinical measures of disease progression.
At the ESC congress, Alnylam said that at month 30, patients on vutrisiran experienced a decline in 6-MWT of 26.46 meters from baseline, while 32.09 meters for the placebo arm.
Subgroup analyses of the primary and secondary endpoints demonstrated generally consistent results across all key patient segments, including patients receiving Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Vyndamax (tafamidis)&nbsp;at baseline.
In patients receiving baseline tafamidis, vutrisiran demonstrated a 22% reduction in the composite primary endpoint of ACM and recurrent CV events and a 41% reduction in ACM at 42 months versus placebo.
Trends toward greater than average benefit were seen in patients with baseline characteristics indicative of early disease.
The company remains on track to proceed with global regulatory submissions for vutrisiran starting later this year, including filing a supplemental New Drug Application with the FDA using a Priority Review Voucher.
BridgeBio Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) has ATTR-CM therapy acoramidis, currently&nbsp;under FDA priority review with an FDA action <a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g36930111/bridgebio-pharma-announces-u-s-food-and-drug-administration-fda-acceptance-of-new-drug-application" rel="noreferrer noopener">date of November 29</a>. BridgeBio Pharma stock jumped&nbsp;in reaction.
Price Action: ALNY stock is down 5.9% at $270.00 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/08/40650305/secureworks-stock-drops-as-dell-weighs-strategic-sale-options" target="_blank" rel="noreferrer noopener">SecureWorks Stock Drops as Dell Weighs Strategic Sale Options</a>.</li>
</ul>

Alnylam Says Typo In Presentation Misstated Heart Drug Benefit

WIIM

Alnylam Pharmaceuticals shares are trading lower. The company announced results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy.

Alnylam Presents Detailed Results From Positive HELIOS-B Phase 3 Study Of Vutrisiran: Achieved 28% Reduction In Primary Composite Of All-cause Mortality And Recurrent Cardiovascular Events, And 31% And 36% Reductions In All-cause Mortality

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 5 years by 13.34% on an annualized basis producing an average annual return of 27.24%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.55 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 5 years ago, it would be worth $326.67 today based on a price of $269.14 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724706021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and raises the price target from $248 to $280.

JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $280

Goldman Sachs analyst Salveen Richter upgrades Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) from Neutral to Buy and raises the price target from $198 to $370.

Upgrades

Goldman Sachs Upgrades Alnylam Pharmaceuticals to Buy, Raises Price Target to $370

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$340.00</td>
<td>$218.4K</td>
<td>641</td>
<td style="text-align: right;">626</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/13/24</td>
<td>$138.00</td>
<td>$77.5K</td>
<td>0</td>
<td style="text-align: right;">381</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$80.00</td>
<td>$729.7K</td>
<td>48</td>
<td style="text-align: right;">358</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$900.00</td>
<td>$72.7K</td>
<td>980</td>
<td style="text-align: right;">296</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$520.00</td>
<td>$26.9K</td>
<td>158</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$64.0K</td>
<td>3.0K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$70.00</td>
<td>$41.7K</td>
<td>2.0K</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$590.00</td>
<td>$37.3K</td>
<td>1</td>
<td style="text-align: right;">28</td>
</tr>
<tr>
<td>ARGX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$530.00</td>
<td>$36.5K</td>
<td>2</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$240.00</td>
<td>$70.0K</td>
<td>609</td>
<td style="text-align: right;">21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option trade that happens to be bullish, expiring in 67 day(s) on October 18, 2024. This event was a transfer of 624 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $218.4K, with a price of $350.0 per contract. There were 641 open contracts at this strike prior to today, and today 626 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option trade that happens to be bullish, expiring in 32 day(s) on September 13, 2024. This event was a transfer of 380 contract(s) at a $138.00 strike. The total cost received by the writing party (or parties) was $77.5K, with a price of $204.0 per contract. There were 0 open contracts at this strike prior to today, and today 381 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option trade with bullish sentiment. It expires in 858 day(s) on December 18, 2026. Parties traded 350 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $729.7K, with a price of $2085.0 per contract. There were 48 open contracts at this strike prior to today, and today 358 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 39 day(s) on September 20, 2024. Parties traded 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $72.7K, with a price of $3639.0 per contract. There were 980 open contracts at this strike prior to today, and today 296 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on August 16, 2024. This event was a transfer of 100 contract(s) at a $520.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $26.9K, with a price of $272.0 per contract. There were 158 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option trade that happens to be bearish, expiring in 522 day(s) on January 16, 2026. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $64.0K, with a price of $640.0 per contract. There were 3010 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 95 day(s) on November 15, 2024. Parties traded 50 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $41.7K, with a price of $835.0 per contract. There were 2099 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option trade that happens to be bearish, expiring in 193 day(s) on February 21, 2025. This event was a transfer of 14 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $37.3K, with a price of $2670.0 per contract. There were 1 open contracts at this strike prior to today, and today 28 contract(s) were bought and sold. 
• For ARGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), we notice a put option trade that happens to be bullish, expiring in 130 day(s) on December 20, 2024. This event was a transfer of 10 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $36.5K, with a price of $3650.0 per contract. There were 2 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding ALNY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on August 16, 2024. Parties traded 20 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $70.0K, with a price of $3500.0 per contract. There were 609 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARGX

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

IOVA

MDGL

MRNA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 10 years by 5.17% on an annualized basis producing an average annual return of 15.53%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.40 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 10 years ago, it would be worth $424.42 today based on a price of $260.17 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723066215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Company To Host Conference Call And Investor Webcast On August 30, 2024

Alnylam Pharmaceuticals To Present HELIOS-B Phase 3 Study Results Of Vutrisiran At ESC Congress 2024; Announces Topline Results Demonstrating Significant Reduction In Mortality And Cardiovascular Events

Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) and increased the price tar...

Alnylam Pharma's Vutrisiran Garners Strong Buy Rating Amidst Positive ATTR-CM Treatment Prospects

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $...

RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Fidelity Capital Appreciation Fund Q2 2024 Review

Fidelity Select Health Care Portfolio Q2 2024 Review

BlackRock Health Sciences Term Trust Q2 2024 Commentary

TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $282.00. The company...

TD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today. The company's shares clos...

Alnylam Pharma (ALNY) Receives a Buy from Bank of America Securities

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more… Over the past two decades, the cost of gene sequencing has plummeted, turning genomics into a cutting-edge field with enormous potential. Thanks to substantial investments and waves of research funding, the industry is making significant strides in understanding and treating a range of genetic disorders and complex diseases.
In this rapidly evolving landscape, fundamentally sound companies like Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>) are at the forefront of transforming healthcare.
Genomics is not just about unlocking the secrets of DNA; it's about applying that knowledge to real-world medical treatments. By understanding the unique genetic code of individuals, doctors can now offer more precise diagnostics and personalized treatments for conditions that range from common cancers to rare genetic disorders. It's an approach that brings us closer to an era of truly personalized medicine, where your DNA guides your healthcare plan.
Sales of next-generation genomic medicines are expected to <a href="https://ascent.usbank.com/private-capital-management/ascent-resources-and-insights/investment-strategies/investing-in-genomics.html">hit $84 billion by 2028</a>, driven by successful clinical trials and the growing need for new treatments. Moreover, the global genomics market is projected to grow from $39.53 billion in 2024 to $157.47 billion by 2033 at a <a href="https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033#:~:text=The%20global%20genomics%20market%20size,period%20(2024%2D2033).">CAGR of 16.6%</a>.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On April 30, 2024, ALNY and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced a further expansion of their existing partnership in Central &amp; Eastern Europe and Israel also to include selected markets in LATAM and APAC and additional international markets.
This partnership is expected to ensure that ALNY's commercial therapies are available across multiple international markets, thus enhancing their income streams.
ALNY's trailing-12-month gross profit and EBIT margins of 87% and 4.38% are 50.5% and 64.7% higher than their respective industry averages of 57.81% and 2.66%. Also, its trailing-12-month levered FCF margin of 18.10% compares to the industry average of 1.60%.
During the fiscal second quarter that ended June 30, 2024, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million versus a year-ago operating loss of $154.03 million. Also, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded last year.
Analysts predict ALNY's revenue for the current year (ending December 2024) to increase 20.5% year-over-year to $2.20 billion. Further, its revenues are expected to register a 13.2% growth from the prior year, settling at $2.49 billion. It is no surprise that the company has topped the consensus revenue estimates in three of the trailing four quarters.
Over the past six months, ALNY's stock has surged 85.3% to close the last trading session at $273.15.
ALNY's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Sentiment and a B for Quality. ALNY is ranked #28 among 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #2: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN develops, manufactures, and markets life science tools and integrated systems for large-scale genetic variation and function analysis. It operates through the Core Illumina and GRAIL segments. It provides sequencing and array-based instruments and consumables, whole-genome sequencing, genotyping, NIPT, and product support services.
On July 9, the company acquired Fluent BioSciences, a company known for its advanced single-cell technology. This acquisition strengthens ILMN's multiomics growth strategy by offering its customers advanced capabilities in single-cell research and enabling them to provide more comprehensive solutions to their customers.
ILMN's trailing-12-month EBIT margin of 4.63% is 80% higher than the industry average of 2.57%. Likewise, its 14.34% trailing-12-month EBITDA margin is 132.7% above the industry average of 6.16%. Also, its trailing-12-month levered FCF margin of 19.39% compares to the industry average of 1.61%.
In the second quarter that ended June 30, 2024, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. The company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
Street expects ILMN's EPS for the fiscal third quarter (ending September 2024) to increase 164.7% year-over-year to $0.87, while its revenue is forecasted to be $1.08 billion. Moreover, it surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $130.97.
ILMN's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It also has a B grade for Growth, Sentiment, and Quality. Within the same industry, it is ranked #24. To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #1: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Its product portfolio includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara solution, and ARCALYST, among other injections.
On September 13, the U.S. Food and Drug Administration (FDA) approved the use of Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older.
The stock's trailing-12-month EBITDA and levered FCF margins of 33.50% and 15.50% are considerably higher than the industry averages of 6.16% and 1.61%, respectively. Similarly, its trailing-12-month EBIT margin of 30.14% compares to the industry average of 2.57%.
REGN's net revenues for the second quarter (ended June 2024) increased 12% year-over-year to $3.55 billion. Its non-GAAP net income grew 14.3% from the year-ago value to $1.35 billion, while its income from operations stood at $1.07 billion, up 5.2% year-over-year. The company's non-GAAP net income per share came in at $11.56, representing a 12.9% year-over-year growth.
The consensus revenue estimate of $3.66 billion for the fiscal third quarter (ending September 2024) represents an 8.7% improvement year-over-year. The consensus EPS estimate of $11.76 for the ongoing quarter represents a 1.5% increase from the same period last year. The company has a promising earnings surprise history, as it surpassed the consensus EPS estimates in three of the trailing four quarters.
Shares of REGN have gained 38.1% over the past year and 29.7% year-to-date.
It is no surprise that REGN has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Value and Quality. Out of 335 stocks in the same industry, it is ranked #8.
In addition to the POWR Rating grades I've just highlighted, you can see REGN's Growth, Momentum, Stability, and Sentiment ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
REGN shares were unchanged in premarket trading Thursday. Year-to-date, REGN has gained 29.66%, versus a 18.86% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/regn-alny-ilmn-3-genomics-stocks-transforming-healthcare/>3 Genomics Stocks Transforming Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomics Stocks Transforming Healthcare

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $300.00. The compa...

American Century Focused Dynamic Growth Fund Q2 2024 Commentary

AAPL

AMGN

AMZN

AVGO

BMEZ

BMYMP

BSQKZ

CABA

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GKOS

GOOG

GOOGL

IMCR

INSP

ISRG

MRUS

MSFT

NFLX

NGNE

NONOF

NVDA

ONEQ

PODD

PRCT

REGN

RHHBF

RHHBY

RHHVF

SARTF

SILK

SOAGY

SSSGY

SUVPF

TSHA

TSLA

UTHR

VEEV

Press Releases

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Issues 2023 Corporate Responsibility Report

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (ALNY) Forecast

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Quote.Headers.trade-ideas